CV 6209

platelet activating factor antagonist; structure given in first source

Also Known As:

2-(N-acetyl-N-(2-methoxy-3-octadecylcarbamoyloxypropoxycarbonyl)aminomethyl)-1-ethylpyridinium; CV 6209 chloride; CV-6209; Pyridinium, 2-(2-acetyl-6-methoxy-3,9-dioxo-4,8-dioxa-2,10-diazaoctacos-1-yl)-1-ethyl-, chloride

Networked: 27 relevant articles (6 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Pyridinium Compounds: 5
      - CV 6209: 27

Experts

1.	Chen, Bing-Mae: 1 article (10/2021)
2.	Luera, Nicholas: 1 article (10/2021)
3.	Lv, Shixian: 1 article (10/2021)
4.	Peeler, David J: 1 article (10/2021)
5.	Pun, Suzie H: 1 article (10/2021)
6.	Roffler, Steve R: 1 article (10/2021)
7.	Sylvestre, Meilyn: 1 article (10/2021)
8.	Yang, Lucy F: 1 article (10/2021)
9.	Evans, William E: 1 article (03/2015)
10.	Fernandez, Christian A: 1 article (03/2015)

Related Diseases

1.	Ischemia 01/01/1993 - "The effects of a PAF antagonist, CV-6209, were evaluated in this study by means of a partial liver ischemia model, in which ischemia was induced by clamping only part of the liver without causing intestinal congestion. " 12/01/1992 - "In the present study, we examined the effect of CV-6209, a specific PAF receptor antagonist, on gastric mucosal injury induced by ischemia-reperfusion, to shed some light on the possible involvement of PAF in such lesions. " 12/01/1992 - "However, CV-6209 had no effect on gastric mucosal blood flow during ischemia-reperfusion. " 06/01/1990 - "CV-6209, a specific PAF antagonist, significantly alleviated gastric mucosal damage and hemodynamic disturbance induced by ischemia-reperfusion. " 03/01/1988 - "Furthermore, the increase in cardiac permeability induced in isolated perfused rat hearts undergoing 15 min global ischemia followed by reperfusion was significantly attenuated by CV-6209 (250 nmol/l). "
2.	Reperfusion Injury 12/01/1997 - "It is suggested that the new PAF antagonist CV-6209 is effective in the prevention of heart and lung ischemia-reperfusion injury with and without allopurinol pretreatment." 12/01/1997 - "The objective of this experimental protocol was to evaluate the protective effect of a new, potent platelet-activating factor (PAF) antagonist CV-6209 and the use of this compound in combination with allopurinol on ischemia-reperfusion injury in a swine model of heart-lung transplantation. "
3.	Wounds and Injuries (Trauma) 01/01/1988 - "CV-6209, at a dose of 1 mg/kg (i.v.) given after trauma, significantly improved survival rate at 150 min and overall survival time. "
4.	Thrombocytopenia (Thrombopenia) 09/01/1990 - "When it was repeatedly administered to pregnant mice during days 1-6 of pregnancy, CV-6209 prevented preimplantation thrombocytopenia and reduced the number of implantation sites dose-dependently, CV-6209 suppression of pregnancy was eliminated by concomitant administrations of PAF. "
5.	Pancreatitis 03/01/1992 - "The role of endogenous platelet-activating factor (PAF) in the pathogenesis of acute pancreatitis was investigated by determining whether CV-6209, a selective PAF antagonist, confers protection against caerulein-induced acute pancreatitis in rats. "

Related Drugs and Biologics

1.	Platelet Activating Factor
2.	Arachidonic Acid (Vitamin F)
3.	Zymosan
4.	Ceruletide
5.	Allopurinol (Remid)
6.	CV 3988
7.	Histamine (Histamine Dihydrochloride)
8.	Serotonin (5 Hydroxytryptamine)
9.	Propranolol (Inderal)
10.	Cromolyn Sodium (Cromoglicic Acid)

Related Therapies and Procedures

1.	Heart-Lung Transplantation
2.	Ligation